Drug intelligence / Profile preview

iXB 401

Development stage: Preclinical
Lead developer: iX Biopharma
Modality: Peptides
Administration: Sublingual

Overview

iXB 401 is a novel sublingual wafer formulation of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, being developed by iX Biopharma for the treatment of type 2 diabetes and obesity. Utilizing the proprietary WaferiX and WaferlogiX drug delivery platforms, iXB 401 is designed to provide a non-invasive alternative to injectable GLP-1 therapies. Preclinical data in Sprague-Dawley rats demonstrated that the sublingual wafer achieved approximately 20 times higher bioavailability compared to the oral semaglutide tablet Rybelsus. By bypassing the gastrointestinal tract, the sublingual route aims to improve patient compliance and potentially reduce side effects associated with oral or injectable administration.

Other names: semaglutide sublingual wafer

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on iXB 401.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iXB 401.

Explore the full profile